Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.66 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.66 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31302456 | 0.92 | GNAI3 (0.59) | GNAI3GNAO1GNAI1TSHRKMT2A | |
| SCHEMBL2324315 | 0.86 | GNAI3 (0.63) | GNAI3GNAO1GNAI1ALDH1A1KDM4E | |
| SCHEMBL1438748 | 0.83 | GNAI3 (0.84) | GNAI3GNAO1GNAI1KMT2AKDM4E | |
| SCHEMBL31302552 | 0.83 | GNAI3 (0.49) | GNAI3GNAO1GNAI1TSHRKMT2A | |
| SCHEMBL2413009 | 0.82 | TSHR (0.55) | GNAI3GNAO1GNAI1TSHRKMT2A | |
| SCHEMBL4555068 | 0.82 | GNAI3 (0.94) | GNAI3GNAO1GNAI1GAANAAA | |
| SCHEMBL30807297 | 0.82 | GNAI3 (0.58) | GNAI3GNAO1GNAI1TSHRKMT2A | |
| SCHEMBL6017191 | 0.81 | GNAI3 (0.97) | GNAI3GNAO1GNAI1NAAA | |
| SCHEMBL13745660 | 0.80 | TSHR (0.72) | GNAI3GNAO1GNAI1TSHRKMT2A | |
| SCHEMBL1438745 | 0.80 | GNAI3 (0.73) | GNAI3GNAO1GNAI1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-09-29 | — | — | US | disclosed |
| EP-2352732-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO Ý4, 3-D¨PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | Merck Patent GmbH (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2009098282-A1 | LOW MOLECULAR WEIGHT 2,5-DISUBSTITUTED THIOPHENE DERIVATIVES AND USE THEREOF IN THERAPY | NOVASAID AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237583-A1 | 2, 5-DIAMINO-SUBSTITUTED PYRIDO [4, 3-D] PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER | ENPP2, PLA2G4A, PLA2G4B | GNAI3 1577/4885GNAO1 1123/4885GNAI1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.